Entrectinib in Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours
机构：[1]Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiao TongUniversity, Shanghai, China[2]Division of Thoracic Oncology, Department of ChestMedicine, Taipei Veterans General Hospital, Taipei, Taiwan[3]Department of MedicalOncology, Harbin Medical University Cancer Hospital, Harbin, China[4]Department ofClinical Oncology, The Chinese University of Hong Kong, Hong Kong, China[5]Departmentof Oncology, National Taiwan University Hospital, Taipei, Taiwan[6]Departmentof Medical Oncology, Shanghai Cancer Center, Fudan University, Shanghai, China[7]Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Scienceand Technology, Wuhan, China华中科技大学同济医学院附属协和医院[8]Department of Medical Oncology, SichuanCancer Hospital, Chengdu, China[9]Department of Thoracic Oncology, Peking UniversityCancer Hospital and Institute, Beijing, China[10]Department of Breast Oncology,Tianjin Medical University Cancer Institute and Hospital, National Clinical ResearchCenter for Cancer, Tianjin Medical University, Tianjin, China[11]Data Science Department,F. Hoffmann-La Roche Limited, Beijing, China[12]Data Science Department, F.Hoffmann-La Roche Limited, Shanghai, China[13]Department of Clinical Science, F.Hoffmann-La Roche Limited, Shanghai, China[14]Department of Clinical Safety, F.Hoffmann-La Roche Limited, Shanghai, China[15]Department of Medical ThoracicOncology, Zhejiang Cancer Hospital, Hangzhou, China浙江省肿瘤医院
第一作者机构：[1]Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiao TongUniversity, Shanghai, China
推荐引用方式(GB/T 7714)：
Lu S.,Chiu C-H.,Yu Y.,et al.Entrectinib in Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours[J].ANNALS OF ONCOLOGY.2022,33:S83-S84.doi:10.1016/j.annonc.2022.02.138.
APA：
Lu, S.,Chiu, C-H.,Yu, Y.,Loong, H. H. F.,Lin, C. C....&Fan, Y..(2022).Entrectinib in Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours.ANNALS OF ONCOLOGY,33,
MLA：
Lu, S.,et al."Entrectinib in Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours".ANNALS OF ONCOLOGY 33.(2022):S83-S84
医学